Some version of this message reaches me almost every week, from patients, from readers, and from the GLP-1 communities I'm part of. It spiked again this month. What follows is a composite paraphrase in my own words, drawn from several people's messages. It is not a verbatim quotation from anyone, but every idea in it is one I've heard:
Is anyone else just tired of hearing about everything that could go wrong on a GLP-1? Every time there's a new headline (this week it's vision loss), the people who love me line up to ask if I've seen it. I know they mean well, but it's draining. I'm working hard on my health, and this medication is helping. Why does it feel like everyone is waiting for something to go wrong? How do you tune it out?
I want to answer that directly. You can take a safety concern seriously without reopening your treatment at every dinner. Here is what the signal is, what to watch for, and what to say to the people who keep asking.
| Clinical Takeaway | |||||||||||||||
|
What NAION is, and what to watch for
The story behind most of these messages is NAION, or non-arteritic anterior ischemic optic neuropathy, an injury to the optic nerve associated with insufficient blood flow. The vision loss it causes is usually permanent, and there is no proven treatment to reverse it. This month's coverage follows hundreds of lawsuits alleging that GLP-1 medications caused it. A lawsuit is not a finding of causation, and it is also not a reason to wave away people who have lost vision.
| The core claim A rare complication is not a trivial complication. The person who experiences it deserves to be taken just as seriously as the person whose health improves with treatment. Knowing the warning signs, and deciding with your clinician, is how you hold both truths at once. |
Here is the part worth memorizing:
Sudden loss of vision, a new missing area of vision, or rapidly worsening eyesight needs urgent assessment, even if there is no pain. Seek emergency eye care immediately; use an emergency department if that is not available.
For other new vision changes, contact your clinician promptly rather than assuming they are a harmless medication effect.
If NAION is confirmed, UK MHRA guidance recommends discontinuing semaglutide, under the direction of your treating team.
Tell your clinicians about your eye history. A previous NAION, or a crowded optic disc noted on a past exam, is worth raising before or during treatment, along with what eye care makes sense for you.
When the people you love keep asking
Most people who forward these stories are frightened for you, not judging you. You can receive the love without taking on the panic. Four things help.
1. Acknowledge the concern. Thank them for looking out for you before you say anything else. It lowers the temperature and tells them they were heard.
2. Give one calm response. You don't owe anyone a debate. Pick the version that fits where you are:
If you're still looking into it:
"Thanks for looking out for me. I'm reviewing this with my clinician. What would help most is your support, rather than more headlines."
If you've already reviewed it:
"I've discussed the risk with my clinician, and I'm comfortable with our plan. I'll revisit it if my health or the evidence changes."
3. Set a boundary when you need one. If it's the same person every time, it's okay to say, "I've heard your concern and I've handled it with my doctor. I'm not going to discuss my medication anymore." Love doesn't require an open forum on your medical decisions. If the headlines themselves are wearing you down, muting a few keywords for a while is a reasonable personal boundary. Keep one trusted channel open, ideally your clinician, so credible new information still reaches you.
4. Bring the real questions to your care team. If a headline genuinely worries you, that's a question for your clinician, not the group chat. Your aunt can't examine your optic nerve; an eye specialist can. It also helps to write down why you started treatment and what has changed since, from your A1c to the stairs you can climb, because that record is useful when you revisit the plan together. Feeling better is real information, but it doesn't rule out a rare side effect, which is why the warning signs above still matter.
What the evidence says
The regulatory finding is clear. In June 2025, the European Medicines Agency concluded that NAION is a very rare adverse effect of semaglutide, and the UK's MHRA issued its own warning in February 2026. Australia's TGA updated product information for several GLP-1 medications in July 2026, which does not establish that the risk is equal across the class. In the U.S., an FDA Sentinel study of GLP-1 medications and NAION is listed as in progress. What remains uncertain is the precise size of the risk, the mechanism, who is most susceptible, and how agents differ. U.S. neuro-ophthalmology societies describe a possible increase and recommend shared decision-making.
The estimates depend on who was studied and how. The 2024 study that first raised the concern (Hathaway et al.) drew entirely from patients seen at one academic neuro-ophthalmology service, a referral population unlike most people starting treatment. In a Danish registry of adults with type 2 diabetes (Grauslund et al.), NAION occurred at approximately 2.3 versus 0.9 cases per 10,000 person-years in people exposed versus not exposed to semaglutide, an observed difference of approximately 1.4 cases per 10,000 person-years. That is a study-specific association, not a proven number of cases caused by treatment, and not an established estimate for every drug, dose, or patient population.
| Semaglutide and NAION · relative measures in three early studies | ||||||
|
||||||
| HR = hazard ratio between groups. IRR = incidence-rate ratio from a self-controlled analysis, comparing exposed and unexposed periods within individuals rather than against a comparator group. All three are observational, and populations differ, so the numbers are not interchangeable. |
Newer studies add evidence without settling the question. Two trial-emulation analyses in Annals of Internal Medicine this July compared new users of GLP-1 medications with new users of other diabetes drugs. In U.S. commercial claims data, Reynolds et al. found approximately 3 to 4 additional diagnoses of ischemic optic neuropathy, a broader category used as a proxy for NAION, per 10,000 people over 18 months. In a Swedish nationwide cohort, Ueda et al. reported one-year risks of anterior ischemic optic neuropathy of approximately 0.04% versus 0.02% compared with SGLT2 inhibitors. Restricting that analysis to people already taking metformin weakened the association and increased the uncertainty; it did not show the drugs have no effect, or measure how much of the difference reflects confounding.
Pointing the other way, a VA cohort (Choi et al.) of older, predominantly male veterans with type 2 diabetes estimated approximately 10 excess NAION diagnoses per 10,000 people over three years among GLP-1 initiators compared with SGLT2 initiators, with the usual observational limits on confounding and diagnostic accuracy. Absolute increases have generally been small in these population studies, but the estimates differ, and no single range marks the boundary of the evidence.
Free · The GLP-1 Evidence Cheat Sheet
Twelve GLP-1 trials on one page, with the effect sizes in one place for the next time you want to check a number yourself.
|
Benefits deserve the same standard
SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease and overweight or obesity, but without diabetes. Over approximately 40 months, cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo. The hazard ratio was 0.80, with an observed absolute difference of 1.5 percentage points, or about 150 fewer people experiencing the combined outcome per 10,000 participants over that period.
That is a result in a specific population, not a promise to any individual reader, and it comes from a different population and time frame than the eye studies, so the two can't be collapsed into a simple trade ratio. The real decision is rarely semaglutide versus nothing. It is which treatment best fits a particular person's risks, expected benefits, alternatives, and preferences.
Stigma is part of why these conversations feel so heavy. People treating obesity, a chronic disease, often field questions that people on other long-term medicines rarely hear. That doesn't mean everyone who raises a safety question is judging you; many are simply worried.
What we still need to learn
| Open questions | ||||||||
|
Much of the evidence estimating this association comes from observational studies. That makes the size of the risk uncertain; it does not make the safety concern illegitimate. And your own history or preferences can change the right decision for you even if the population estimate never moves.
The bottom line
You can take a safety concern seriously without turning every forwarded headline into a referendum on your treatment. You're allowed to ask questions, revisit the plan with your clinician, and ask the people who love you for support. You do not have to defend your care at every dinner. You do deserve care that takes both benefits and risks seriously.
Disclosure: The author is Chief Medical Officer of Vineyard, a telehealth obesity medicine practice. This article is educational and is not individualized medical advice. Sudden loss of vision, a new missing area of vision, or rapidly worsening eyesight needs emergency eye care immediately, even without pain; use an emergency department if eye care is not available. Contact your clinician promptly about other new vision changes, and talk with your own clinician before making changes to your care.
| From Vineyard: if you’re exploring obesity care, see how Vineyard approaches it → |
REFERENCES
1. Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-9. doi:10.1001/jamaophthalmol.2024.2296
2. Grauslund J, Taha AA, Molander LD, Kawasaki R, Möller S, Højlund K, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10(1):97. doi:10.1186/s40942-024-00620-x
3. Cai CX, Hribar M, Baxter S, Goetz K, Swaminathan SS, Flowers A, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4):304-14. doi:10.1001/jamaophthalmol.2024.6555
4. Reynolds KR, O'Malley KM, Roy JA, Dave CV. Glucagon-like peptide-1 receptor agonists and risk for ischemic optic neuropathy: a target trial emulation. Ann Intern Med. 2026;179(9):1244-53. doi:10.7326/ANNALS-25-00860
5. Ueda P, Svanström H, Söderling J, Pazzagli L, Wintzell V, Eliasson B, et al. Glucagon-like peptide-1 receptor agonists and risk for anterior ischemic optic neuropathy: a nationwide cohort study. Ann Intern Med. 2026;179(9):1232-43. doi:10.7326/ANNALS-25-02096
6. Choi T, Al-Aly Z, Xie Y. GLP-1 receptor agonists or SGLT2 inhibitors and nonarteritic anterior ischemic optic neuropathy. JAMA Netw Open. 2026;9(4):e269917. doi:10.1001/jamanetworkopen.2026.9917
7. DeParis SW, Oke I, Gaier ED, Moss HE, MacIntosh PW, Gilbert AL, et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8):1029-35. doi:10.1016/j.ophtha.2026.04.008
8. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy [Internet]. Amsterdam: EMA; 2025 Jun 6.
9. Medicines and Healthcare products Regulatory Agency. Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischemic optic neuropathy (NAION). Drug Safety Update. 2026 Feb 5.
10. Therapeutic Goods Administration. GLP-1 RAs and rare vision disorder [safety update]. 2026 Jul 23.
11. Sentinel Initiative, US Food and Drug Administration. Risk of non-arteritic anterior ischemic optic neuropathy (NAION) following glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes mellitus [Internet]. Status: in progress. Available from: https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-non-arteritic-anterior-ischemic-optic-neuropathy-naion
12. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-32. doi:10.1056/NEJMoa2307563 (SELECT; NCT03574597)
Evidence-based obesity medicine, twice a week. No hype, no telehealth grifts.
